Form 4: Aldeyra Therapeutics Director Granted Over 65,000 Stock Options

Aldeyra Therapeutics, Inc. Director Neal Walker was granted a total of 65,141 stock options with an exercise price of $2.685, vesting over one year subject to continued service.

Summary

• Neal Walker, a Director of Aldeyra Therapeutics, Inc. (ALDX), was granted a total of 65,141 stock options on June 10, 2025.
• The stock options have an exercise price of $2.685 per share.
• A tranche of 62,728 options will become 100% exercisable on the one-year anniversary of the grant date (June 10, 2026), contingent upon Mr. Walker's continuous service as a member of the Board of Directors.
• An additional 2,413 options will also become 100% exercisable on the one-year anniversary of the grant date (June 10, 2026), provided Mr. Walker maintains continuous service as a member of the Compensation Committee of the Board of Directors.
• All granted options are set to expire on June 9, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal as it aligns the director's interests with shareholder value and incentivizes long-term commitment. It's a routine compensation event, so not extremely positive, but certainly not negative.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value creation of Aldeyra Therapeutics.
• The one-year vesting schedule, tied to continuous service, incentivizes the director's ongoing commitment and contribution to the company's governance and strategic direction.

Risks

• The value of the granted stock options is contingent on Aldeyra Therapeutics' common stock price exceeding the exercise price of $2.685 per share in the future.
• The vesting of the options is subject to the reporting person providing continuous service as a director and compensation committee member through the applicable vesting date, meaning forfeiture could occur if service ceases.

Future Outlook

The grant of performance-based stock options to a director suggests an expectation of continued service and aligns the director's incentives with the company's long-term performance, implying a positive outlook on future stock appreciation.

Industry Context

This is a routine insider transaction (stock option grant) common in the biotechnology and pharmaceutical industries to compensate and incentivize directors and executives. Such grants are a standard component of executive compensation packages, aiming to align management interests with shareholder value creation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of the director's interests with long-term stock performance.

Next Steps

• Neal Walker's continued service as a Director and Compensation Committee member through June 10, 2026, for the options to vest.
• Potential exercise of options by Neal Walker at or after the vesting date and before the expiration date.

Key Dates

Keywords

Aldeyra Therapeutics, ALDX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership